Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
NCT05625724

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Led by University Hospital, Toulouse · Updated on 2026-05-07

1164

Participants Needed

21

Research Sites

299 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

CONDITIONS

Official Title

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Nulliparous women aged 18 years or more
  • Pregnancy following assisted reproductive technology (ART), including IVF, ICSI, oocyte donation, or intrauterine insemination with sperm donor
  • Singleton pregnancy
  • Pregnancy between 9 and 14 weeks of gestation
  • Affiliated to French Social Security Insurance or equivalent
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Major fetal abnormality
  • Regular aspirin treatment (including for antiphospholipid syndrome)
  • Allergies or contraindications to aspirin such as von Willebrand disease, peptic ulceration, or hemophilia
  • Women legally protected by law
  • Participation in another interventional study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 21 locations

1

CHU Angers

Angers, France

Actively Recruiting

2

CHU Bordeaux

Bordeaux, France

Actively Recruiting

3

CHU Clermont-Ferrand

Clermont-Ferrand, France

Actively Recruiting

4

CHU Dijon-Bourgogne

Dijon, France

Actively Recruiting

5

CHU Lille

Lille, France

Actively Recruiting

6

HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant

Lyon, France

Actively Recruiting

7

AP-HM Hôpital de la Conception

Marseille, France

Actively Recruiting

8

AP-HM Hôpital Nord

Marseille, France

Actively Recruiting

9

CHU Montpellier

Montpellier, France

Actively Recruiting

10

CHRU Nancy

Nancy, France

Actively Recruiting

11

CHU Nantes

Nantes, France

Actively Recruiting

12

CHU Nîmes

Nîmes, France

Actively Recruiting

13

Groupe hospitalier St Joseph

Paris, France

Actively Recruiting

14

Hôpital Armand - Trousseau

Paris, France

Not Yet Recruiting

15

Hôpital Cochin

Paris, France

Actively Recruiting

16

CHI Poissy Saint Germain en Laye

Poissy, France

Actively Recruiting

17

CHU Poitiers

Poitiers, France

Not Yet Recruiting

18

CHU Rennes

Rennes, France

Actively Recruiting

19

CHU Saint Etienne, Hôpital Nord

Saint-Etienne, France

Actively Recruiting

20

CHU Strasbourg

Strasbourg, France

Actively Recruiting

21

CHU Toulouse

Toulouse, France

Actively Recruiting

Loading map...

Research Team

P

Paul GUERBY, MD

CONTACT

D

Delphine DUCHANOIS, Midwife

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology | DecenTrialz